U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939295) titled 'Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study' on Nov. 10.
Brief Summary: Evaluate the safety and tolerability of stereotactic injection of KL002 into the putamen of patients with advanced primary PD.
Study Start Date: Jan., 2027
Study Type: INTERVENTIONAL
Condition:
Parkinson's Disease (PD)
Advanced Primary PD
Intervention:
GENETIC: Injecting KL002 into the bilateral putamen
KL002 is a recombinant adeno-associated virus (rAAV9) vector carrying TH, GCH1, and AADC genes
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Kanglin Biotechnology (Hangzhou) Co., Ltd.
Published by HT Digital Content S...